Ambrx Pipeline

Ambrx has a number of products at various stages of development in its pipeline, with a focus on “best in class” and ‘first in class” product candidates. The company’s lead program ARX-201, is a long-acting human growth hormone (hGH) that is currently in phase II clinical trials. ARX-201 is administered once-weekly, a notable improvement over current once-daily hGH therapies. This program is partnered with EMD Serono. Our second most advanced project is ARX424 for the treatment of multiple sclerosis. This project is also being advanced under a strategic collaboration with EMD Serono. ARX424 has demonstrated enhanced in vivo potency (> 2-fold) and pharmacokinetics (19-fold increased exposure) when compared to marketed products from this class of proteins. We believe that both of these molecules represent “best in class” opportunities on commercially validated targets. Ambrx has multiple other protein and antibody product candidates that target a variety of diseases such as cancer, diabetes, CNS disorders and obesity all advancing towards clinical development. Additional antibody drug conjugate projects in oncology are anticipated to be initiated during 2010. We are targeting three to four clinical stage programs by mid- 2010.